Bowhead Specialty Holdings Inc.
NYSE:BOWInsurance - Property & Casualty
-$0.11 today
- Market cap
- $1.13B
- Beta
- -0.01
- P/E (TTM)
- 15.4
- EPS (TTM)
- $1.78
Volume 0.10M
Average 0.19M
BOW Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Bowhead Specialty Holdings Inc.NYSE: BOW
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Research & Development vs competitors
How BOW compares with its peers on the latest reported figures
- BOW's LTM Mar 2026 research & development of $0 is the highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for BOW, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BOWBowhead Specialty Holdings Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BOW) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for BOW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 187.6M | 283.42M | 425.59M | 551.54M |
| Cost of Revenue | 126.96M | 187.22M | 280.5M | 374.54M |
| Gross Profit | 60.65M | 96.2M | 145.1M | 177M |
| Gross Margin | 32.3% | 33.9% | 34.1% | 32.1% |
| Research & Development | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 |
| Operating Expenses | 45.99M | 64.09M | 94.56M | 109.71M |
| Depreciation & Amortization | 727K | 2.27M | 3.87M | 1.78M |
| EBITDA | 15.39M | 34.38M | 55.13M | 71.09M |
| EBITDA Margin | 8.2% | 12.1% | 13.0% | 12.9% |
| Operating Income | 14.66M | 32.12M | 50.54M | 67.3M |
| Operating Margin | 7.8% | 11.3% | 11.9% | 12.2% |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 725K | 2.01M |
| Other Income / Expenses | 0 | 0 | 0 | 0 |
| Income Before Tax | 14.66M | 32.12M | 50.54M | 67.3M |
| Pre-Tax Margin | 7.8% | 11.3% | 11.9% | 12.2% |
| Income Tax Expense | 3.41M | 7.07M | 12.29M | 13.51M |
| Net Income | 11.26M | 25.05M | 38.24M | 53.79M |
| Net Margin | 6.0% | 8.8% | 9.0% | 9.8% |
| EPS (Basic) | 0.36 | 0.79 | 1.31 | 1.64 |
| EPS (Diluted) | 0.36 | 0.79 | 1.29 | 1.59 |
| Weighted Avg Shares | 31.53M | 31.53M | 29.26M | 32.78M |
| Weighted Avg Shares (Diluted) | 31.53M | 31.53M | 29.68M | 33.65M |
Bowhead Specialty Holdings Inc.
NYSE:BOW
Intrinsic Alpha fair value
Locked
Current Price
$34.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.